AML‐BFM Registry 2017

• Recording of all AML diseases and their treatment in children and adolescents in the participating centers of all participating countries
• Recording the genetic, molecular genetic and epigenetic characteristics of AML in children and adolescents
• Determination of minimal residual disease (MRD) by means of morphology, immunophenotyping and molecular genetics
• Determination of the frequency and kinetics of molecular relapse

The registry is intended to comprehensively record all diseases of children and adolescents with AML and their treatment as well as the cytogenetic, molecular genetic and epigenetic characteristics of AML in children and adolescents. The treatment response to a standardized therapy can also provide important insights into the characterization of AML. Furthermore, the frequency and kinetics of molecular relapse during and after completion of intensive chemotherapy should be recorded, so that the MRD load in peripheral blood should be determined on a monthly basis.

Treatment recommendations

The registry serves exclusively to collect data; no explicit treatment recommendations are made. Patients should be treated according to the recommended standard therapy.

• Age from 0 - 17 years
• de novo AML, myelosarcoma, acute mixed lineage leukaemia / biphenotypic leukaemia (dominant myeloid according to WHO 2008) or
• AML as a second malignancy or
• transient leukaemia and myeloid leukaemia with trisomy 21 or
• relapsed/refractory AML in children and adolescents or
• "special" cases of AML-associated diseases after consultation and approval by the registry center
• admission to an accredited paediatric oncology center according to GBA resolution "Paediatric Oncology"
• availability of all necessary informed consent forms

• Missing informed consent from the patient and/or the legal guardian